Dupilumab: He lāʻau lapaʻau e pale ana i ka maʻi maʻi maʻi

He Haʻawina no ka pale ʻana i ka Eczema

ʻO ka dermatitis atopic, a i ʻole kekahi ʻano kikoʻī o ka eczema, ʻike ʻia e kahi maʻi ʻeha a hoʻopilikia. Hōʻike ka poʻe i loaʻa i kēia maʻi ʻili e noho me ka ʻeha mau, ka ʻeha, a lawe pinepine i ka ʻeha nui ma ko lākou mau kino. ʻO ka mea pōmaikaʻi, ʻo ka puka ʻana mai o kahi lāʻau hou he mea maʻi kupaianaha me nā hopena kupaianaha, me nui ka poʻe i komo i loko o ka hoʻokolokolo e hōʻike ana i ka emi ʻana o ka ʻulaʻula, ka ʻili, a me ka pehu ma ko lākou kino.

Ma kahi noiʻi makapō ʻelua, ua hāʻawi ʻia kahi hapakolu o nā mea maʻi i nā pana placebo, ʻo kekahi hapakolu i hāʻawi ʻia i nā injections i loaʻa ka lāʻau, Dupilumab, hoʻokahi manawa i ka pule, a ua hāʻawi ʻia ka hui hope i kahi pana o ka lāʻau i kēlā me kēia pule no kahi pule. huina o 16 mau pule.

Ma kahi kokoke i 40% o nā maʻi i hōʻike i ka hoʻomaikaʻi ʻana i ko lākou ʻili, me ka hapa nui o nā 60% ʻē aʻe e ʻōlelo ana e ʻike i kekahi ʻano hoʻonui.

E loaʻa koke i nā poʻe maʻi i komo ʻole i ka hoʻokolokolo ke pōmaikaʻi mai ka lāʻau?

Ua ʻōlelo ʻo Kauka George D. Yancopoulos, he ʻepekema ma Regeneron, e hoʻoholo ka Food and Drug Administration inā kūpono ʻo Dupilumab no ka hāʻawi ʻana i ka lā Malaki 29, 2017.

Ke nīnau ʻia ka nui o Dupilumab e manaʻo ʻia e uku, Ua ʻōlelo ʻo Kauka Yancopoulos i ka New York Times e "kūlike me ka waiwai o ka lāʻau."  Eia nō naʻe, no ka mea he mea olaola ka lāʻau lapaʻau, ʻo ia hoʻi he genetically engineered me ka hoʻohana ʻana i nā genetics kanaka, hiki ke paʻakikī ke hana, e lilo ia i huahana makemake nui a pipiʻi. ʻO ia hoʻi, pono paha ka mea maʻi e uku i ke kālā liʻiliʻi no ke kūʻai ʻana i ka lāʻau lapaʻau i hana nui ʻia.

Ua mahalo ʻo Dupilumab i ka poʻe ...

ʻOiai he kiʻekiʻe paha ke kumukūʻai mākeke o Dupilumab, he mea kupanaha nā hopena, e waiho ana i ka poʻe maʻi lōʻihi o ka eczema me ka hauʻoli me ko lākou ʻili i hoʻomaʻemaʻe ʻia.

Ma waho aʻe o nā hoʻomaikaʻi ʻike ʻia o nā kūlana ʻili, ua hoʻonui pū ʻo Dupilumab i ka manaʻo ponoʻī o ka mea maʻi. ʻO ka poʻe he nui i loaʻa i ka eczema e haʻi i ka hopena noʻonoʻo e pili ana iā lākou, me ke kaumaha a me nā pilikia hilinaʻi koʻikoʻi. Ua hana pū ʻo Dr. Jon M. Hanifin, ke kaukaʻi o ka dermatology ma Oregon Health and Science University, me kekahi o nā maʻi i komo i ka hoʻokolokolo, e hōʻike ana i ka hauʻoli o ka nui o nā maʻi i pili. e ʻōlelo ana "hele mākou i loko o ka lumi a ʻakaʻaka nā maʻi. ʻO kēia mau maʻi ka mea ʻino loa. Ua luku ʻia ko lākou ola.

ʻAʻole e haʻi ʻia, ua hoʻokaʻawale ka FDA i kēia lāʻau lapaʻau hou ma ke ʻano he "breakthrough therapy". Hiki i kēia lepili ke hoʻoulu i nā luna kānāwai FDA e kamaʻāina a ʻike iā Dupilumab, hiki ke kōkua i ka ʻae ʻana i ka lāʻau lapaʻau ma ka lā hoʻoholo o Malaki.